Abiopharma

🔍 Provoost Jonathan (Executive)

Company: AMARIN CORP PLC\UK (AMRN)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 3,688 shares of American Depositary Shares (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: false | shares_owned_after: 3,688.00 | transaction_form_type: 4 | Footnotes: F1, F2, F1, F3, F1
• Sold 1,488 shares of American Depositary Shares at $13.96 per share (Direct)
  Date: 2026-01-02 | Code: F | equity_swap_involved: false | shares_owned_after: 2,200.00 | transaction_form_type: 4 | Footnotes: F1, F4, F1, F1
• Acquired 3,688 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-02 | Code: A | equity_swap_involved: false | shares_owned_after: 3,688.00 | transaction_form_type: 4 | Footnotes: F5, F1, F2, F3, F1, F1, F1

Footnotes:

• F1: Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change.
• F2: On January 10, 2025, the Reporting Person was granted 7,376 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2020 Stock Incentive Plan (the "Plan"). The shares subject to this grant shall vest over eighteen months, with 50% to vest on January 2, 2026 and the remaining balance to vest on July 1, 2026.
• F3: Not applicable.
• F4: Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
• F5: Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.